Universities are among the oldest institutions in the world. In America, most of the highest-ranked universities were founded in the 19th century or earlier. Despite their age, universities need to innovate, perhaps now more than ever, to serve evolving societal needs, modernize through use of technology, stay financially viable, and fulfill their missions. University innovation is more than inventorship, technology transfer, and commercialization. It entails developing a culture that stimulates novel and integrated change through education, research, and public service as well as clinical care, athletics, the arts, and various auxiliary activities. This article shows how innovation appears in university rankings and in university mission statements, providing insights into how universities can become innovative universities.
{"title":"Creating the Innovative University","authors":"R. Hall","doi":"10.21300/21.4.2020.3","DOIUrl":"https://doi.org/10.21300/21.4.2020.3","url":null,"abstract":"Universities are among the oldest institutions in the world. In America, most of the highest-ranked universities were founded in the 19th century or earlier. Despite their age, universities need to innovate, perhaps now more than ever, to serve evolving societal needs, modernize through\u0000 use of technology, stay financially viable, and fulfill their missions. University innovation is more than inventorship, technology transfer, and commercialization. It entails developing a culture that stimulates novel and integrated change through education, research, and public service as\u0000 well as clinical care, athletics, the arts, and various auxiliary activities. This article shows how innovation appears in university rankings and in university mission statements, providing insights into how universities can become innovative universities.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"27 1","pages":"1-14"},"PeriodicalIF":0.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87304293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher Wiedeman, Huidong Xie, X. Mou, Ge Wang
Artificial intelligence (AI) and machine learning (ML), especially deep learning, have generated tremendous impacts throughout our society, including the tomographic medical imaging field. In contrast to computer vision and image analysis, which have been major application examples of deep learning and deal with existing images, tomographic medical imaging mainly produces cross-sectional or volumetric images of internal structures from sensor measurements. Recently, deep learning has started being actively developed worldwide for medical imaging, including both tomographic reconstruction and image analysis. While medical imaging is a well-established field, in which extensive teaching experience has been accumulated over the past few decades, updating the medical imaging course to reflect AI/ML influence is a new challenge given the rapidly changing landscape of AI-based medical imaging, particularly deep tomographic imaging. In the 2019 fall semester, the medical imaging course at Rensselaer Polytechnic Institute was modified to include an AI framework with positive feedback from students. Encouragingly, many students showed a strong motivation to learn AI in classes and hands-on projects, as confirmed in their survey reports. In the 2020 fall semester, we improved this course further, incorporating new advances. This article describes our teaching philosophy, practice, and considerations with respect to integrating deep learning, tomographic imaging, and hands-on programming to redefine the medical imaging course. Furthermore, given the persistent pandemic, online teaching and examination have become an integral part of higher education. These needs will be addressed as well, with the hope of developing an open course in the future.
{"title":"Innovating the Medical Imaging Course","authors":"Christopher Wiedeman, Huidong Xie, X. Mou, Ge Wang","doi":"10.21300/21.4.2020.5","DOIUrl":"https://doi.org/10.21300/21.4.2020.5","url":null,"abstract":"Artificial intelligence (AI) and machine learning (ML), especially deep learning, have generated tremendous impacts throughout our society, including the tomographic medical imaging field. In contrast to computer vision and image analysis, which have been major application examples\u0000 of deep learning and deal with existing images, tomographic medical imaging mainly produces cross-sectional or volumetric images of internal structures from sensor measurements. Recently, deep learning has started being actively developed worldwide for medical imaging, including both tomographic\u0000 reconstruction and image analysis. While medical imaging is a well-established field, in which extensive teaching experience has been accumulated over the past few decades, updating the medical imaging course to reflect AI/ML influence is a new challenge given the rapidly changing landscape\u0000 of AI-based medical imaging, particularly deep tomographic imaging. In the 2019 fall semester, the medical imaging course at Rensselaer Polytechnic Institute was modified to include an AI framework with positive feedback from students. Encouragingly, many students showed a strong motivation\u0000 to learn AI in classes and hands-on projects, as confirmed in their survey reports. In the 2020 fall semester, we improved this course further, incorporating new advances. This article describes our teaching philosophy, practice, and considerations with respect to integrating deep learning,\u0000 tomographic imaging, and hands-on programming to redefine the medical imaging course. Furthermore, given the persistent pandemic, online teaching and examination have become an integral part of higher education. These needs will be addressed as well, with the hope of developing an open course\u0000 in the future.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"202 1","pages":"1-11"},"PeriodicalIF":0.5,"publicationDate":"2020-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77036603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Software patents have garnered a lot of attention in recent years due, at least in part, to the proliferation of software-enabled devices, such as smartphones and tablets, and the use of software to control a range of devices from automobiles to kitchen appliances. Enforcement of software patents involves unique legal issues that should be considered before asserting a patent against an accused infringer. A primary issue to consider is whether the patent claims are still patent-eligible under recent changes in the law. Also, certain types of software patents are vulnerable to attack in U.S. Patent Office proceedings, but these proceedings are not available unless the patent owner takes step to provoke them. In addition, software inventions are often implemented as method patents, which have unique requirements and restrictions that should be considered. For example, steps of a method patent must all be performed by an accused infringer in the United States and must all be performed by the same entity (or under the direction or control of that entity). Where a software invention is not implemented as a method patent, pre-suit damages may not be available unless the patentee's own products are properly marked with the patent number, and software has very different requirements for marking than more tangible products. A careful consideration of each of these issues is essential before moving forward with a lawsuit.
{"title":"Issues to Consider Before Asserting A Software Patent","authors":"M. Greenbaum, S. Herrman","doi":"10.21300/21.3.2020.205","DOIUrl":"https://doi.org/10.21300/21.3.2020.205","url":null,"abstract":"Software patents have garnered a lot of attention in recent years due, at least in part, to the proliferation of software-enabled devices, such as smartphones and tablets, and the use of software to control a range of devices from automobiles to kitchen appliances. Enforcement of software\u0000 patents involves unique legal issues that should be considered before asserting a patent against an accused infringer. A primary issue to consider is whether the patent claims are still patent-eligible under recent changes in the law. Also, certain types of software patents are vulnerable\u0000 to attack in U.S. Patent Office proceedings, but these proceedings are not available unless the patent owner takes step to provoke them. In addition, software inventions are often implemented as method patents, which have unique requirements and restrictions that should be considered. For\u0000 example, steps of a method patent must all be performed by an accused infringer in the United States and must all be performed by the same entity (or under the direction or control of that entity). Where a software invention is not implemented as a method patent, pre-suit damages may not be\u0000 available unless the patentee's own products are properly marked with the patent number, and software has very different requirements for marking than more tangible products. A careful consideration of each of these issues is essential before moving forward with a lawsuit.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"4 1","pages":"205-212"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78279059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
237 We present a case of a university invention and the long, costly legal process that was required to challenge prominent infringing products. This history highlights a number of areas where reforms are urgently needed so that small entities can defend their intellectual property with realistic budgets, timelines, and solid facts—and without baseless recriminations. A call for coordinated action is made to restore the ability of the National Academy of Inventors members and other inventors and small entities to access the law in defense of issued patents.
{"title":"Infringement Battles: A Case Study Illustrates The Need for Reforms","authors":"Kevin J. Parker","doi":"10.21300/21.3.2020.237","DOIUrl":"https://doi.org/10.21300/21.3.2020.237","url":null,"abstract":"237 We present a case of a university invention and the long, costly legal process that was required to challenge prominent infringing products. This history highlights a number of areas where reforms are urgently needed so that small entities can defend their intellectual property with realistic budgets, timelines, and solid facts—and without baseless recriminations. A call for coordinated action is made to restore the ability of the National Academy of Inventors members and other inventors and small entities to access the law in defense of issued patents.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"14 1","pages":"237-241"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81490454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This article presents a case study of patent litigation involving an individual academic inventor and three manufacturers that were using her invention and marketing it worldwide. The article provides an overview of the invention, the patent covering it, and the manner in which the case was handled at different levels in the U.S. courts. A brief discussion of the recent trends in restricting patent litigation and some recommendations for improving and streamlining the process are provided. In addition, some of the possible impacts of implementing recently suggested measures that bear on the ability of individual and academic inventors to assert their patent rights are also discussed.
{"title":"How the U.S. Courts View the Rights of Individual Patentees: A Case Study","authors":"F. Tehrani","doi":"10.21300/21.3.2020.229","DOIUrl":"https://doi.org/10.21300/21.3.2020.229","url":null,"abstract":"This article presents a case study of patent litigation involving an individual academic inventor and three manufacturers that were using her invention and marketing it worldwide. The article provides an overview of the invention, the patent covering it, and the manner in which the\u0000 case was handled at different levels in the U.S. courts. A brief discussion of the recent trends in restricting patent litigation and some recommendations for improving and streamlining the process are provided. In addition, some of the possible impacts of implementing recently suggested measures\u0000 that bear on the ability of individual and academic inventors to assert their patent rights are also discussed.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"149 1","pages":"229-236"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77482481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The NAI Profile: An Interview With Dr. Dereje Agonafer","authors":"D. Agonafer, Kimberly A. Macuare","doi":"10.21300/21.3.2020.251","DOIUrl":"https://doi.org/10.21300/21.3.2020.251","url":null,"abstract":"","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"33 1","pages":"251-258"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86272399","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The NAI Chapter Spotlight: Virginia Commonwealth University","authors":"I. Metcheva, Kimberly A. Macuare","doi":"10.21300/21.3.2020.259","DOIUrl":"https://doi.org/10.21300/21.3.2020.259","url":null,"abstract":"","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"515 1","pages":"259-262"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86867049","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"From the USPTO: A New Publication Offers Inventors and Businesses Guidance on Protecting Their Intellectual Property in China","authors":"S. Perlmutter","doi":"10.21300/21.3.2020.247","DOIUrl":"https://doi.org/10.21300/21.3.2020.247","url":null,"abstract":"","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"11 1","pages":"247-249"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89572153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Universities have long recognized the need to create pathways for ideas and new technologies to advance from academic labs to market; however, the decentralized and haphazard nature of American innovation means that some discoveries may be neglected. In order to more effectively address the issues with innovation, a research team led by Steven Currall produced a new framework in the book Organized Innovation: A Blueprint for Renewing America's Prosperity. Because of the current drive of universities to increase innovation, economic development, and corporate partnerships, we thought it was timely to revisit this book and offer commentary on its lessons for navigating these demands.
{"title":"An Idea That Has Come of Age—Organized Innovation: a Blueprint for Renewing America's Prosperity","authors":"P. Sanberg, K. Burg","doi":"10.21300/21.3.2020.243","DOIUrl":"https://doi.org/10.21300/21.3.2020.243","url":null,"abstract":"Universities have long recognized the need to create pathways for ideas and new technologies to advance from academic labs to market; however, the decentralized and haphazard nature of American innovation means that some discoveries may be neglected. In order to more effectively address\u0000 the issues with innovation, a research team led by Steven Currall produced a new framework in the book Organized Innovation: A Blueprint for Renewing America's Prosperity. Because of the current drive of universities to increase innovation, economic development, and corporate partnerships,\u0000 we thought it was timely to revisit this book and offer commentary on its lessons for navigating these demands.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"24 1","pages":"243-246"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89508195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Some patents confront infringement—unauthorized use of the inventions in the patent—thus violating the exclusive use intent of the U.S. Constitution's creation of the patent system to encourage innovation. In other situations, the reverse occurs—patent holders seek to extend their exclusivity period to prevent competitive entrants. This commonly occurs in biopharmaceutical products markets, where annual revenues on many patented drugs exceed $1 billion per year and (most importantly) where several pathways allow extension of exclusivity. This paper reviews the relevant legislation (Bayh-Dole Act, Orphan Drug Act, Hatch-Waxman Act, and Food and Drug Administration (FDA) Modernization Act) as well as the safety and efficacy regulations of the FDA that control marketing of biopharmaceutical products. The paper then assesses methods used to extend patent exclusivity—some legal, some clearly illegal, and some with ambiguous legal status—in order to deter generic entrants. These methods include using FDA "citizen's petitions," creating generic equivalents of branded drugs to block other generic entrants, deterring potential generic competitors from gaining samples to prove bioequivalence to original formulations, seeking additional patents to extend exclusivity (sometimes for trivial changes), paying potential entrants to delay entry, subdividing the potential patient population to qualify for extensions granted by "orphan drug" status, and (most recently) selling patents to Native American tribes to prevent challenges to their validity. The paper concludes by discussing remedies—primarily legislative—that could either eliminate these actions and/or clarify their legality. Then follows a comparison between these entry-delaying strategies and patent infringement itself.
{"title":"Extending Exclusivity for Biopharmaceuticals to Deter Competing Generics: A Review of Strategies, Potential Mitigation, and Similarities to Infringement","authors":"C. Phelps","doi":"10.21300/21.3.2020.215","DOIUrl":"https://doi.org/10.21300/21.3.2020.215","url":null,"abstract":"Some patents confront infringement—unauthorized use of the inventions in the patent—thus violating the exclusive use intent of the U.S. Constitution's creation of the patent system to encourage innovation. In other situations, the reverse occurs—patent holders seek\u0000 to extend their exclusivity period to prevent competitive entrants. This commonly occurs in biopharmaceutical products markets, where annual revenues on many patented drugs exceed $1 billion per year and (most importantly) where several pathways allow extension of exclusivity. This\u0000 paper reviews the relevant legislation (Bayh-Dole Act, Orphan Drug Act, Hatch-Waxman Act, and Food and Drug Administration (FDA) Modernization Act) as well as the safety and efficacy regulations of the FDA that control marketing of biopharmaceutical products. The paper then assesses methods\u0000 used to extend patent exclusivity—some legal, some clearly illegal, and some with ambiguous legal status—in order to deter generic entrants. These methods include using FDA \"citizen's petitions,\" creating generic equivalents of branded drugs to block other generic entrants, deterring\u0000 potential generic competitors from gaining samples to prove bioequivalence to original formulations, seeking additional patents to extend exclusivity (sometimes for trivial changes), paying potential entrants to delay entry, subdividing the potential patient population to qualify for extensions\u0000 granted by \"orphan drug\" status, and (most recently) selling patents to Native American tribes to prevent challenges to their validity. The paper concludes by discussing remedies—primarily legislative—that could either eliminate these actions and/or clarify their legality. Then\u0000 follows a comparison between these entry-delaying strategies and patent infringement itself.","PeriodicalId":44009,"journal":{"name":"Technology and Innovation","volume":"43 1 1","pages":"215-227"},"PeriodicalIF":0.5,"publicationDate":"2020-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77726080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}